41 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
23 Jun 23
2023 Annual General Meeting of Shareholders
4:15pm
insurance policy equivalent to an amount up to 13-1/3% of his gross monthly salary, up to 2-1/2% of his gross monthly salary for disability insurance … -competition agreement is indefinite, unless earlier terminated for just cause by either party, upon the death, disability or retirement age, or without cause
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
25 Nov 22
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
7:12am
% for the placebo. The discontinuation rate was significantly higher for Otezla than for Piclidenoson. In achieving psoriasis disability index (PDI) response
6-K
EX-99.1
4quus
12 Sep 22
Report of Foreign Private Issuer
7:02am
6-K
EX-99.3
u2uwher
25 Aug 22
Report of Foreign Private Issuer
7:16am
6-K
EX-99.1
szuixj1
22 Aug 22
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
7:05am
6-K
EX-99.1
u1m bqooo5q
11 Jul 22
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
7:13am
6-K
EX-99.1
6dzo 2k8ev6
29 Jun 22
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORTTM Study in Moderate to Severe Psoriasis
7:09am
424B4
b10v4fhml25
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
xi82kin2ax1t8wb
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
2dquk8
24 Jan 20
Registration statement (foreign)
4:40pm
20-F/A
zyu2dz
2 Apr 19
Annual report (foreign) (amended)
6:52am
424B3
9isltk7b
22 Mar 19
Prospectus supplement
4:50pm
F-1/A
6960ot07eq5dno
12 Mar 19
Registration statement (foreign) (amended)
4:20pm